Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 16/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832723 | 1.00 | GRM2 (0.55) | GRM2HPGDTSHRSIRT1MAPK1 | |
| SCHEMBL10572097 | 0.88 | GRM2 (0.52) | GRM2HPGDTSHRSIRT1MAPK1 | |
| SCHEMBL11744593 | 0.87 | GRM2 (0.63) | GRM2HPGDTSHRSIRT1MAPK1 | |
| SCHEMBL12356873 | 0.86 | GRM2 (0.57) | GRM2HPGDTSHRMAPK1L3MBTL1 | |
| SCHEMBL8948258 | 0.86 | GRM2 (0.54) | GRM2HPGDTSHRSIRT1 | |
| SCHEMBL12356902 | 0.86 | GRM2 (0.54) | GRM2HPGDTSHRSIRT1 | |
| SCHEMBL2832784 | 0.86 | GRM2 (0.54) | GRM2HPGDTSHRSIRT1MAPK1 | |
| SCHEMBL6869635 | 0.84 | GRM2 (0.57) | GRM2 | |
| SCHEMBL3851718 | 0.84 | GRM2 (0.46) | GRM2 | |
| SCHEMBL29067786 | 0.83 | GRM2 (0.51) | GRM2HPGDTSHRSIRT1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166847-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2166847-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156718-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-4886794-A | ANTIHISTAMINES, ANTIALLERGENS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0291244-A1 | Cyclic carbamate derivatives | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | GRM2 4870/4885HPGD 3203/4885TSHR 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.